Suppr超能文献

耐碳青霉烯肠杆菌科细菌在有和无医疗保健风险因素个体中的分布情况-美国,2012-2015 年。新兴传染病项目。

Carbapenem-Resistant enterobacterales in individuals with and without health care risk factors -Emerging infections program, United States, 2012-2015.

机构信息

Centers for Disease Control and Prevention, Atlanta, GA.

Centers for Disease Control and Prevention, Atlanta, GA.

出版信息

Am J Infect Control. 2023 Jan;51(1):70-77. doi: 10.1016/j.ajic.2022.04.003. Epub 2022 Jul 28.

Abstract

BACKGROUND

Carbapenem-resistant Enterobacterales (CRE) are usually healthcare-associated but are also emerging in the community.

METHODS

Active, population-based surveillance was conducted to identify case-patients with cultures positive for Enterobacterales not susceptible to a carbapenem (excluding ertapenem) and resistant to all third-generation cephalosporins tested at 8 US sites from January 2012 to December 2015. Medical records were used to classify cases as health care-associated, or as community-associated (CA) if a patient had no known health care risk factors and a culture was collected <3 days after hospital admission. Enterobacterales isolates from selected cases were submitted to CDC for whole genome sequencing.

RESULTS

We identified 1499 CRE cases in 1194 case-patients; 149 cases (10%) in 139 case-patients were CA. The incidence of CRE cases per 100,000 population was 2.96 (95% CI: 2.81, 3.11) overall and 0.29 (95% CI: 0.25, 0.35) for CA-CRE. Most CA-CRE cases were in White persons (73%), females (84%) and identified from urine cultures (98%). Among the 12 sequenced CA-CRE isolates, 5 (42%) harbored a carbapenemase gene.

CONCLUSIONS

Ten percent of CRE cases were CA; some isolates from CA-CRE cases harbored carbapenemase genes. Continued CRE surveillance in the community is critical to monitor emergence outside of traditional health care settings.

摘要

背景

耐碳青霉烯肠杆菌科(CRE)通常与医疗保健相关,但也正在社区中出现。

方法

在美国 8 个地点,从 2012 年 1 月至 2015 年 12 月,开展了主动、基于人群的监测,以鉴定培养物中对碳青霉烯(不包括厄他培南)不敏感且对所有第三代头孢菌素均耐药的肠杆菌科患者病例。使用病历将病例分类为医疗保健相关病例,如果患者没有已知的医疗保健危险因素且培养物在入院后 <3 天采集,则将其分类为社区相关(CA)病例。从选定的病例中分离出肠杆菌科分离株,并提交给 CDC 进行全基因组测序。

结果

我们在 1194 名病例患者中发现了 1499 例 CRE 病例,在 139 名病例患者中有 149 例(10%)为 CA 病例。每 100,000 人口的 CRE 病例发生率为 2.96(95%CI:2.81,3.11),CA-CRE 为 0.29(95%CI:0.25,0.35)。大多数 CA-CRE 病例为白人(73%),女性(84%),并从尿培养物中分离出来(98%)。在 12 例测序的 CA-CRE 分离株中,有 5 株(42%)携带碳青霉烯酶基因。

结论

10%的 CRE 病例为 CA 病例;一些 CA-CRE 病例的分离株携带碳青霉烯酶基因。对社区中 CRE 的持续监测对于监测传统医疗保健环境以外的出现至关重要。

相似文献

2
Multispecies emergence of dual carbapenemase-producing Enterobacterales recovered from invasive infections in Chile.
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0120524. doi: 10.1128/aac.01205-24. Epub 2024 Dec 5.
3
Clinical and genomic characterization of carbapenem-resistant bloodstream infections in patients with hematologic malignancies.
Front Cell Infect Microbiol. 2024 Sep 26;14:1471477. doi: 10.3389/fcimb.2024.1471477. eCollection 2024.
4
Molecular Characterization of Carbapenem-Resistant Enterobacterales Collected in the United States.
Microb Drug Resist. 2022 Apr;28(4):389-397. doi: 10.1089/mdr.2021.0106. Epub 2022 Feb 16.
6
Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study.
Clin Microbiol Infect. 2023 May;29(5):629-634. doi: 10.1016/j.cmi.2023.01.005. Epub 2023 Jan 12.
7
Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Strains, Including Carbapenem-Resistant Isolates.
Microbiol Spectr. 2023 Feb 14;11(1):e0450722. doi: 10.1128/spectrum.04507-22. Epub 2023 Jan 9.
8
Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013.
JAMA. 2015 Oct 13;314(14):1479-87. doi: 10.1001/jama.2015.12480.
10
Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018.
Eur J Clin Microbiol Infect Dis. 2020 Jul;39(7):1287-1294. doi: 10.1007/s10096-020-03845-4. Epub 2020 Mar 2.

引用本文的文献

1
Risk factors for Carbapenem-resistant Enterobacterales infections: A case-control study.
S Afr Fam Pract (2004). 2025 Feb 7;67(1):e1-e10. doi: 10.4102/safp.v67i1.6029.
5
Carbapenemase producing at a large teaching hospital in Ohio: comparison to state surveillance and retrospective analysis of patient characteristics.
Infect Prev Pract. 2024 Apr 27;6(2):100366. doi: 10.1016/j.infpip.2024.100366. eCollection 2024 Jun.
7
Emergence of pandrug-resistant carbapenemase-producing in dogs and cats: a cross-sectional study in Egypt.
Front Cell Infect Microbiol. 2024 Mar 18;14:1318585. doi: 10.3389/fcimb.2024.1318585. eCollection 2024.
8
Trends in Incidence of Carbapenem-Resistant Enterobacterales in 7 US Sites, 2016─2020.
Open Forum Infect Dis. 2023 Dec 5;10(12):ofad609. doi: 10.1093/ofid/ofad609. eCollection 2023 Dec.

本文引用的文献

5
The etiology and management of recurrent urinary tract infections in postmenopausal women.
Climacteric. 2019 Jun;22(3):242-249. doi: 10.1080/13697137.2018.1551871. Epub 2019 Jan 9.
7
Clinical Practice Guidelines for the Antibiotic Treatment of Community-Acquired Urinary Tract Infections.
Infect Chemother. 2018 Mar;50(1):67-100. doi: 10.3947/ic.2018.50.1.67.
8
Carbapenem-Nonsusceptible Acinetobacter baumannii, 8 US Metropolitan Areas, 2012-2015.
Emerg Infect Dis. 2018 Apr;24(4):727-734. doi: 10.3201/eid2404.171461.
10
Diagnosis and treatment of urinary tract infections across age groups.
Am J Obstet Gynecol. 2018 Jul;219(1):40-51. doi: 10.1016/j.ajog.2017.12.231. Epub 2018 Jan 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验